Scholarlink

<p>&#xa0;This report describes the first successful administration of ravulizumab, a C5 complement inhibitor, in the treatment of life-threatening intravascular hemolysis (IVH) caused by delayed hemolytic transfusion reaction (DHTR) in a 22-year-old woman. The patient developed acute IVH with severe anemia and hemodynamic instability seven days after receiving a blood transfusion for posthemorrhagic anemia following a missed abortion. Laboratory investigations revealed anti-e and anti-Jka alloantibodies consistent with DHTR. Despite treatment, her hemoglobin level declined further, raising concerns for hyperhemolytic syndrome. After the administration of ravulizumab, her condition improved rapidly, and she was discharged with stable hemoglobin levels. Within three weeks there was full hematologic and biochemical recovery. This case demonstrates the therapeutic potential of ravulizumab in the management of severe complement-mediated hemolysis due to DHTR, and highlights the need for further research on complement inhibitors in similar conditions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ravulizumab stabilizes life-threating intravascular hemolysis following delayed hemolytic transfusion reaction due to alloantibodies anti-e and anti-Jka: the first successful administration

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月28日

查看全文
  • Zoe Bezirgiannidou,
  • Iliana Stamatiou,
  • Theodoros M. Theodoridis,
  • Eftychia Kontekaki,
  • Emmanouil Panagiotopoulos,
  • Christina Misidou,
  • George Vrachiolias,
  • Bouse Malkots,
  • Menelaos Papoutselis,
  • Ioannis Kotsianidis,
  • Emmanouil Spanoudakis,
  • Konstantinos Liapis

摘要

 This report describes the first successful administration of ravulizumab, a C5 complement inhibitor, in the treatment of life-threatening intravascular hemolysis (IVH) caused by delayed hemolytic transfusion reaction (DHTR) in a 22-year-old woman. The patient developed acute IVH with severe anemia and hemodynamic instability seven days after receiving a blood transfusion for posthemorrhagic anemia following a missed abortion. Laboratory investigations revealed anti-e and anti-Jka alloantibodies consistent with DHTR. Despite treatment, her hemoglobin level declined further, raising concerns for hyperhemolytic syndrome. After the administration of ravulizumab, her condition improved rapidly, and she was discharged with stable hemoglobin levels. Within three weeks there was full hematologic and biochemical recovery. This case demonstrates the therapeutic potential of ravulizumab in the management of severe complement-mediated hemolysis due to DHTR, and highlights the need for further research on complement inhibitors in similar conditions.